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Abstract 
Liposomes not only offer the ability to enhance drug delivery, but can effectively act as vaccine 
delivery systems and adjuvants. Their flexibility in size, charge, bilayer rigidity and composition 
allows for targeted antigen delivery via a range of administration routes. In the development of 
liposomal adjuvants, the type of immune response promoted has been linked to their physico-
chemical characteristics, with the size and charge of the liposomal particles impacting on liposome 
biodistribution, exposure in the lymph nodes and recruitment of the innate immune system. The 
addition of immunostimulatory agents can further potentiate their immunogenic properties. Here, 
we outline the attributes that should be considered in the design and manufacture of liposomal 
adjuvants for the delivery of sub-unit and nucleic acid based vaccines. 
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1. Developing new vaccines 
Vaccines remain the most cost-effective way to prevent infectious diseases. Due to the development 
of effective vaccines we have seen the global eradication of smallpox (declared in 1980) and more 
recently Rinderpest (also known as cattle plague, an infectious viral disease of cattle, declared in 
2011). Vaccination has also promoted the dramatic reduction in the instances of polio, diphtheria, 
tetanus, pertussis, measles, mumps and rubella. Despite this success story, infectious diseases cause 
approximately 25 % of world mortality [1]. In the development of new vaccines, we have a range of 
vector options available. Live attenuated, can offer lifelong immunity, and strong humoral and cell 
mediated protection. However, these vaccines are not appropriate for immunocompromised people 
and there is a risk that live attenuated vaccines can revert to their virulent form.  In contrast, 
inactivated vaccines offer improved safety profiles but cannot provide effective long-term protection 
from pathogens [2] due to the destruction of the pathogen replication and transformation 
mechanisms [3, 4], often resulting in the need for high and multiple dose treatments. Similarly, sub-
unit vaccines have a good safety profile but lower potency.  To address this issue, adjuvants can be 
employed to enhance and/or prolong immune responses. Whilst their mechanism of action is yet to 
be fully elucidated, vaccine adjuvants can function through a range of mechanisms including formation 
of a depot, enhancing antigen delivery, uptake and presentation to appropriate antigen presenting 
cells, and induction of stimulatory cytokines and chemokines. There are a range of adjuvant systems 
already in use including aluminium based adjuvants which have been used in vaccines since the 1930s. 
More recentlǇŶĞǁĂĚũƵǀĂŶƚƐƐƵĐŚEŽǀĂƌƚŝƐ ?ƐD& ? ? ?ĂŶŽŝů-in-water emulsion consisting of squalene, 
dǁĞĞŶ ? ?ĂŶĚ^ƉĂŶ ? ? ? ?'^< ?Ɛ^K ? ?ĂƐƋƵĂůĞŶĞ ?dǁĞĞŶ ? ?ĂŶĚɲ-Tocopherol oil-in-water emulsion) 
and ASO4 (Aluminium hydroxide and monophosphoryl lipid A), and the Virosomes system of Berna 
Biotech have been used in licensed vaccines [5]. However despite these advances, to tackle newly 
emerging diseases and re-emerging diseases, there is a continued need for new adjuvants.  
 
1.1. Liposomes as vaccine adjuvants. 
Particulate drug delivery systems offer the potential to act as adjuvants. They offer the ability to 
incorporate sub-unit antigens within pathogen-sized particles that protect antigens from degradation 
and facilitate delivery to antigen presenting cells. Of the particulate drug delivery systems available, 
liposomes were the first system described to offer adjuvant action with their immunological role and 
adjuvant properties being identified by Allison and Gregoriadis (1974) [6]. In these studies, it was 
noted that negatively charged liposomes incorporating dicetyl phosphate were able to potentiate 
immune responses against diphtheria toxoid. Since this seminal work by Allison and Gregoriadis into 
the use of liposomes as adjuvants, all manner of vesicle size, charge and bilayer design have been 
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investigated for their efficacy. Yet, liposomes are not the only bilayer vesicles offering adjuvant 
properties. Whilst phosphatidylcholines are generally the most common lipids employed, a wide range 
of lipids have been investigated to prepare vesicles such as niosomes (e.g. [7]) , virosomes (e.g. [8]) 
and bilosomes (e.g. [9]). These variations on a theme can offer different attributes. For example, 
incorporation of bile salts into the bilayer of vesicles (to form bilosomes) can improve oral delivery of 
vaccines by preventing natural stomach digestive enzymes from disrupting the vesicles. Alternatively, 
virosomes incorporating virus derived proteins promote cell fusion and delivery of viral antigens and 
have been successfully licenced as adjuvants in vaccines against Hepatitis A and Influenza [10].  
However despite this, the development and application of liposomes as adjuvants is currently limited 
to two vaccine systems based on virosomes - Inflexal (against influenza) and Epaxal (against hepatitis 
A). 
 
2. Liposomal adjuvants ʹ how can we use our knowledge of their mechanisms of action to 
drive their development? 
By limiting microbial growth, the innate immune system is a powerful system that is essential in the 
early stages of defence against immune challenge.  However, it also drives the development of 
adaptive immune responses that are essential to enabling the body to clear any given pathogen.   The 
innate immune system comprises many factors, both cellular (e.g. dendritic cells, macrophages, mast 
cells and neutrophils) and soluble (i.e. humoral) factors that can coordinate cellular responses.  It is 
the integration with the adaptive immune system that underlies the functional significance of the 
innate immune system. 
 
When developing novel vaccines, the ability to stimulate the innate immune responses needs to be 
considered.  For live vaccines, this happens naturally with growth of any live attenuated organisms.  
However where no live, active infection occurs, the immune system requires additional stimulation in 
the form of adjuvants.  Liposomal adjuvants have been known to function by offering both protection 
and enhanced delivery of the vaccine antigen and depending on their design they can promote antigen 
presentation and/or facilitate the formation of a depot resulting in attraction of antigen presenting 
cells that engulf antigen and become activated (Fig 1).  
 
2.1 Physico-chemical attributes that can impact of liposomal adjuvant action. 
To improve antigen delivery to antigen presenting cells there are a wide variety of lipids available 
ranging from natural or synthetic, cationic or anionic, unsaturated or saturated, long or short chain, 
single or double chain; and these can all be used in a range of combinations. The choice of lipid used 
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in the formulation and the manufacturing method can all influence the physico-chemical attributes of 
the liposomes formed. This in turn influences their adjuvant action; it is recognised that cellular 
uptake, antigen processing and the presentation by antigen presenting cells are partially dictated by 
these particle characteristics [11]. There are a range of physico-chemical factors that should be 
considered in the design of liposomes as adjuvants. For example, the choice of lipid used can impact 
on the fluidity of the liposomes bilayers. The location and degree of hydrocarbon chain saturation, in 
addition to hydrocarbon chain length, all affect the strength of the van de Waals forces that hold 
adjacent chains together within the bilayer. Hence longer chain length lipids tend to form rigid ordered 
bilayer structures whilst those with shorter tails will become fluid and disorganized. To consider the 
impact of bilayer fluidity on liposomal adjuvant activity, Maxumdar and Ali [12], investigated the 
protective efficacy of liposome encapsulated Leishmania Donovani antigens. They tested three 
different liposomes formulations prepared from distearyol derivative of l-ɲ-phosphatidyl choline 
(DSPC) (with a liquid crystalline transition temperature of 54oC), dipalmitoyl phosphatidyl choline 
(DPPC) (transition temperature of 41oC) and dimyristoyl (DMPC) (Tc 23oC) for their ability to entrap 
Leishmania donovani membrane antigens and to potentiate strong antigen-specific antibody 
responses [12]. The authors demonstrated improved adjuvant activity with DSPC liposomes (95% 
protection in mouse challenge studies), with almost no protection in mice immunised with antigen in 
DPPC or DMPC liposomes. This effect of changing membrane fluidity may affect the adjuvant activity 
through both cellular interactions and biodistribution. Within our studies we also demonstrated that 
rigid liposomes prepared using dimethyldioctadecylammonium (DDA) bromide lipid promoted 
stronger immune responses that more fluid liposomes prepared using the unsaturated analog 
dimethyldioleoylammonium bromide (DODA), which contained one unsaturated C=C bound in each 
of the lipophilic acyl chains [13]. In biodistribution studies, the rigid DDA-based liposomes were shown 
to promote higher levels of antigen at the injection site, resulting in a continuous attraction of antigen-
presenting cells that expressed elevated levels of the co-stimulatory molecules CD40 and CD86 [13]. 
Indeed the rigid, DDA-liposomes induced 100-fold higher Th1 responses than the fluid DODA liposome 
counterparts. 
 
Inclusion of cholesterol within liposomes is also known to influence bilayer fluidity and is commonly 
incorporated within liposome formulations for drug delivery, as it can enhance liposome bilayer 
stability by inserting in the lipid bilayer and stabilise the system [14]. However, in terms of the impact 
of liposomal adjuvant action the effect of cholesterol is unclear; whilst some studies have shown 
improvements in the immune response [15, 16], others have noted reduced responses [17, 18].  
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Vesicle size has also been shown to influence liposomal adjuvant efficacy and studies have shown that 
vesicle size can influence the development of the immune responses towards a Th1 or Th2 cytokine 
profile via a range of routes [19-23]. For example, studies have described enhanced Th2 responses 
after administration of smaller particles whilst larger particles promote IFN-ɶ ĂŶĚ ƚǇƉŝĐĂů dŚ ?
responses [19, 20]. This may be a result of differences in particle trafficking to local lymph nodes and 
uptake by antigen presenting cells, with larger vesicles (650 nm) showing improved antigen tracking, 
processing and antigen presentation  compared to smaller (155 nm) vesicles [21]. Similarly, uptake of 
particulates by DC was only observed at the injection site when large (0.5  W  ?ʅŵ ?ƉĂƌƚŝĐůĞƐǁĞƌĞƵƐĞĚ
rather than small (20  W 200 nm) particles [22]. In recent studies, we have also shown that the size of 
cationic liposomal adjuvants is a controlling factor for pharmacokinetics and biodistribution, which 
dictates the resulting immune response [24]. Differences in the draining of liposomes of different sizes 
was observed in vivo using small liposomes below 200 nm, medium sized vesicles between 500  W 600 
nm and large multilamellar vesicles in the micrometer range. In these studies, significantly higher 
amounts of the 200 nm liposomes were noted at the popliteal lymph node, 6 hours after injection. 
However, there did not result in differences in cellular phagocytosis, as macrophage uptake of the 
liposomes was not size-dependent [24]. In terms of immune responses, vesicle size did not impact on 
antibody production, but a positive correlation of size with cell proliferation rates and an inverse 
correlation on IL-10 production was noted.  
 
Antigen location and liposomal charge have also been shown to influence liposomal adjuvant activity. 
Early work by Gall and colleagues identified a range of cationic lipids capable of disrupting cell 
monolayers, causing haemolysis of sheep red blood cells and damage to tissue at the injection site 
[25]. The lipids identified have long (> 12) carbon chain lengths and cationic in nature. In particular, 
lipids with a quaternary ammonium head group showed high levels of activity. Whilst a cationic 
surface charge can present issues when administered intravenously, due to aggregation and rapid 
clearance by the mononuclear phagocyte system, when administered via other routes this is less of a 
concern. Indeed, when adopted within a liposomal adjuvant formulation, their cationic nature can 
promote sub-unit antigen binding to the liposome surface and stimulate interaction with the anionic 
surface of APC and have been shown to promote strong adaptive immune responses [26] compared 
to neutral formulations that tend to promote a humoral based response [27]. Furthermore, the 
aggregation of cationic liposomes after injection may also to be part of their success as vaccine 
adjuvants given that their aggregation upon injection will result in a depot-effect whereby liposome 
and consequently antigen are retained in the tissue for an extended period of time [28]. However, 
anionic lipids may also offer advantages to the formulation of liposomal adjuvants.  Anionic lipids are 
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known to be recognised by macrophages with a number of specific phosphatidylserine (PS) receptors 
being identified.  Much of this work arises from the study of apoptotic cell clearance where PS is 
exposed on the outer leaflet of the plasma membrane as cells die. Early work indicated that artificial 
PS-containing liposomes may mediate anti-inflammatory/tolerogenic effects in APC and consequently 
PS may not induce the desired downstream APC response.  Anionic surface charges for oral vaccination 
may also offer advantages given the anionic nature of the muscosal barrier which can interact with 
cationic moieties [29, 30] and work by Shakweh et al suggests that negatively charged or neutral 
ƉĂƌƚŝĐůĞƐŝŶŵŝĐĞŚĂǀĞĂŐƌĞĂƚĞƌĂĨĨŝŶŝƚǇĨŽƌƚŚĞWĞǇĞƌ ?ƐƉatches than positively charged particles [31].  
    
Overall, it is clear that the physicochemical characteristics of liposomal adjuvant, as summarised in 
Figure 2, can modulate adjuvant efficacy. However, the ideal parameters required for an optimised 
liposomal adjuvant are yet to be confirmed. This is not surprising given the vast array of lipid 
combinations/liposome constructs that can be considered, and that the impact of these 
characteristics will be multi-factorial. Furthermore, effective adjuvants must not only promote antigen 
delivery, they must also promote cellular interactions and activation of APC. To achieve this, one must 
consider more than the liposome physico-chemical characteristics.  
 
2.2 Designing liposomes with enhanced immunostimulatory activity 
To move beyond physical attributes and develop stronger liposomal adjuvants, a clear understanding 
of the different stages that occur in the development of a protective innate immune response is 
required.  An essential component of the innate immune system is pattern recognition via pattern 
recognition receptors (PRR) [32].  Self/non-self recognition is a central decision point in immunology.  
Why do we respond to some antigens and not others?  From an adjuvant/vaccine development 
perspective, an answer to this question is paramount.  The old-fashioned model of self/non-self 
discrimination has long been queried and many developments to the theories of immune recognition 
have occurred [33].  However a most important stride in our understanding came from the work of 
Charles Janeway who proposed ƚŚĂƚƚŚĞŝŶŶĂƚĞŝŵŵƵŶĞƐǇƐƚĞŵĚŝƐĐƌŝŵŝŶĂƚĞĚ ?ŶŽŶ-ƐĞůĨ ? ? ?ŝŶĨĞĐƚŝŽƵƐ
non-ƐĞůĨ ? ?ĨƌŽŵ ?ƐĞůĨ ? ? ?ŶŽŶ-ŝŶĨĞĐƚŝŽƵƐƐĞůĨ ? ?ĂƚƚŚĞƉŽŝŶƚŽĨƌĞĐŽŐŶŝƚŝŽŶ[34].  That is to say, infectious 
agents were foreign and exposed patterns are evolutionarily conserved (so called pathogen-
associated molecular patterns or PAMPs) and such PAMPs were proposed to be recognised by pattern 
recognition receptors (PRR).  The net result of this work is to highlight the importance of PRR ligation 
to activate cells of the innate immune system [35].  Specifically this refers to the need to activate 
quiescent antigen presenting cells (APC e.g. dendritic cells, macrophages and B cells).  Dendritic cells 
are perhaps the most important APC as they activate naïve T lymphocytes and thus are a key cellular 
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link between the innate and adaptive immune systems.    DC are highly phagocytic cells that eat both 
self and non-self material but direct different responses.  Uptake of self (e.g. apoptotic cells) will drive 
tolerance [36, 37] but whilst this can also occur through the use of PRR [38] [39], it is the ability of 
pathogens via PRR ligation to signal to activate the DC that enables a strong immune response to 
follow.  Crucially this will use the Toll-like receptors and NOD-like receptors type PRR.  Naturally it is 
essential that an adjuvant/vaccine formulation acts to drive strong immunogenic responses rather 
than tolerance and synthetic PRR agonists have been predicted to be the most efficacious [40]. A good 
example of the drive for PRR ligation is the use of monophosphoryl lipid A (MPL), a modification of the 
endotoxic lipid A of LPS (a TLR agonist).  MPL drives PRR signalling and immune cell activation but is 
significantly less toxic than LPS. As such MPL was the first licensed TLR agonist to be used in a vaccine 
formulation (Fendrix (hepatitis B) and Cervarix (human papilloma virus) and has also been included in 
ůŝƉŽƐŽŵĂůĨŽƌŵƵůĂƚŝŽŶƐĞ ?Ő ?ŝŶƚŚĞ'^<ĨŽƌŵƵůĂƚŝŽŶ^ ? ?ǁŚĞƌĞ ? ?-O-desacyl- ? ?-monophosphoryl lipid 
A is combined with a liquid suspension of liposomes is association with a further immunostimulatory 
component (QS21).  Liposomes are particularly well suited to the incorporation of immunostimulatory 
agents that are able to bind to PRRs, for example bacterial modelled glycolipids such as MPL and TDB. 
Inclusion of such substances in adjuvant formulations can improve their immunostimulatory abilities 
in a synergistic manner [41]. Table 1 lists some PAMP-containing liposomal formulations and their 
respective PRRs currently being investigated.  
 
By understanding this basic immune cell biology, we can better design adjuvant formulations.  Such 
developments may target different PRR and perhaps multiple PRR to ensure strong and appropriate 
immune cell activation.  Importantly, our insight to the cell biology of immune cell activation permits 
us to design a series of assays to pre-screen formulations for likelihood of success in vivo.  Clearly, an 
adjuvant that fails to stimulate maturation of quiescent DC or activation of macrophages in vitro is not 
likely to be successful in vivo.  This represents a simple concept but one that may help drive high-
throughput screening of libraries of novel formulations.   
 
At a simple level, one could consider that the necessary steps that are required for a liposomal 
adjuvant to stimulate a protective immune response via activation of APC are: 
1. Attraction of APC: DC and macrophages are migratory cells that may be induced to migrate to 
given stimuli.  Liposomal preparations that incorporate chemoattractants may be of value.  
Naturally occurring vesicles shed from dying cells have been shown to attract macrophages 
[62-64] but this is a prelude to a tolerogenic event [37].  However, the incorporation of 
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established chemoattractants for macrophages (that may also be activators) is of potential 
benefit in promoting APC involvement. 
2. Interaction with APC: APC constitutively sample their environment and the ability of a 
liposome to interact with an APC will be an essential pre-requisite to subsequent steps.  The 
nature of the uptake may be important too.  Liposomes that drive fusion with APC plasma 
membranes (so called fusogenic liposomes) will deliver their contents to the cytoplasm of 
APC, an event that is likely to promote involvement of MHC class I and Tc lymphocytes. 
However, liposomes that drive their own phagocytic uptake (e.g. via scavenger receptors or 
other innate immune receptors) will promote class II MHC involvement and, via cross 
presentation, class I MHC.  Thus targeting of liposomes to different uptake pathways may 
provide a mechanism for tailoring of immune responses. 
3. APC Activation/Maturation: the activation of otherwise quiescent APC is a key event in driving 
protective immune responses.  Liposome formulations that mediate this activation e.g. 
through ligation of PRR (that may also mediate interaction with and uptake of liposomes) are 
likely to be active assuming they are capable of targeting APC.  It is the targeting of this step 
of the process that has driven adjuvant formulations to target the most highly studied PRR the 
TLRs.  
Therefore to manipulate liposomes further to drive their interaction with DC and macrophages 
inclusion of components  which are immunomodulatory to the innate immune system can be 
considered. Due to their versatile structure, it is easy to include various lipophilic components such as 
bacterial derived glycolipids in the bilayered membrane, or surface bound nucleotide based 
molecules, both of which are known to stimulate the immune system. In particular, the use of in toll-
like receptors and their natural and synthetic agonists, many of which can be incorporated into 
liposome design with the aim to produce immunostimulatory antigen delivery systems. Similarly, 
there is the option of tagging liposomes with Ig to drive ligation with Fc receptors or sugars to drive 
interactions with lectin like molecules on APC.  Despite all the significant insight into the interaction 
of cells, pathogens and liposomes with APC, it seems likely that there will not be a single, simple 
feature that can be used to promote liposome/APC interactions and drive immunogenic responses.  
Indeed a variety of liposome formulations may likely permit different, tailored immune responses to 
be promoted that might be beneficial for individual diseases.   
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3. Using liposomes to deliver nucleic acid-based vaccines 
In addition to subunit vaccines, nucleic acid based formulations also have the potential to circumvent 
many of the limitations of live and inactivated vaccines. The advantages of nucleic acids as the active 
component of a vaccine are evident when the mechanics of their activity are understood. To start, out 
of an entire pathogenic genome, we are aware of specific genes that encode for antigenic proteins 
that can then be isolated [65]. In many cases where pathogens have numerous antigenic sites the 
most preferred antigen for a safe and comprehensive immune response may be chosen and its gene 
sequence isolated. By amplifying and expressing this gene encoding antigen, purified samples of the 
selected antigen can be produced. Importantly, by introducing the isolated gene into the host 
organism itself the genetic material can be taken up by the host cells and expressed in vivo. The cell 
can then use its own components and apparatus to synthesize the antigen [66]. A major benefit to this 
is that the internal production of antigen allows for the antigen to be introduced to the immune 
system via the MHC class-I pathway [65] while still allowing for the traditional MHC class-II pathway 
to act [66]. Transforming host cells into antigen producers has other benefits: first, the production of 
new antigen within the host over time means that the initial dose load can be reduced [67], this initial 
dose may also provide a longer term protection in some cases removing previous need for boosters 
[68]. These vaccine formulations also bypass the major limiting factor of attenuated vaccines - the 
complexity of some pathogenic genomes. As that genome is being reduced to the bare essential 
antigenic coding sequences before dosing, potentially any pathogen for which the genome has been 
mapped could be converted into a nucleic acid vaccine.  
 
Despite the above advantages DNA vaccines initially performed poorly in clinical trials; however, a 
small number of DNA vaccine products have now been approved, but all in the veterinary field [69]. 
More recently, self-amplifying RNA technology is showing the strongest promise. The use of RNA 
offers advantages in terms of their simple structure, the fact they can be delivered directly into the 
cytoplasm, and they do not require nuclear localisation to generate expression [70]. These systems 
have been shown to promote strong  responses, for example Geall et al., [71], used lipid nanoparticles 
to deliver the RNA encoding respiratory syncytial virus fusion glycoprotein (RSV) and found this system 
promoted broad, potent and protective immune responses [71].  
 
With these nucleic-acid based vaccines, how the genetic material is introduced into the host is an 
important factor for consideration. While free DNA is able to transfect cells and methodologies have 
been devised to facilitate its uptake without a vector [72], it has been shown that vector-delivered 
DNA vaccines have a higher efficacy [73]. Introducing foreign free DNA to the host without any 
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protective coating vector raises the potential for an improper immune response. Instead of the DNA 
reaching the target cells, being transfected and producing the necessary antigen, the DNA can instead 
be recognised as an antigen itself. Toll-like receptor 3 has been shown to recognise viral double-
stranded DNA as an antigen [74], while Toll-like receptor 7 [75] and Toll-like receptor 8 [76] recognises 
viral single-stranded RNA.  In this case the immune system would then mount an immune response 
not against the chosen antigen but for the genetic material that encodes that antigen; the desired 
antigen-binding antibodies being replaced with anti-DNA antibodies, although not at high enough 
levels to cause any auto-immune complications [77].  An additional problem is one of stability. For 
RNA,  naked insertion into a host system can lead to quick degradation, limiting the vaccines ability to 
spread in the extracellular environment [78]. To avoid these limitations a form of protective vector 
construct must be used to deliver the genetic material to the target in the way that a pathogen would. 
This vector may also need a different cellular uptake pathway to sub-unit systems described above 
given that we require production of the antigen in the first instance. There are numerous approaches 
to be considered in this field; among them antibody derived vectors [79], viral envelope derived 
vectors [80] and carbon nanotube carrier vectors [81]. Each approach will, with further investigation, 
present its own array of advantages and disadvantages surrounding their compositions, delivery 
mechanics and vector-genetic material interactions. Taking viral-like vectors as an example, 
inappropriate management of surface components may limit effectiveness. 
 
In developing a vaccine that utilises nucleic acid components, the vector must be effectively designed 
so that it can interact with, protect and deliver this material to targets as efficiently as possible. In 
order to achieve this, a vector design system allowing for a high degree of customisation to allow for 
these variables is needed; liposomes have numerous factors that make them suitable vectors for 
nucleic acid delivery. Their components, characteristics and additional elements can be altered and 
characterised so that an optimal DNA or RNA delivery mechanism can be created. To start, the lipid 
components suitable for this purpose are limited by a few factors. Importantly, charge dynamics have 
to be considered. Nucleic acids are anionic in nature; therefore for strong vector/vaccine interactions 
to occur the liposomes must contain a component that is cationic to provide a charged bonding 
between the two constituent elements. Cationic liposomes have been shown to make effective 
vectors [82] with several lipids capable of fulfilling the role of cationic component. However an issue 
with cationic liposomes is that of toxicity. Some cationic lipids have been shown to have greater 
immunogenic effects than others, such as DDA [83] and stearylamine [84]; many of the formulations 
used today using DOTAP, DOTMA and DC-Chol have in comparison been shown to have limited 
immunogenicity [85]. There is also evidence that cationic lipids of an anti-inflammatory effect [86], 
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which could result in a down-regulation of macrophage activity at the site of injection leading to an 
altered immune response pathway. 
 
 In addition to a cationic factor, to create a formulation that has a greater transfection efficacy it is 
advisable to include a component to facilitate this. Fusogenic lipids create membrane/membrane 
interactions that facilitate the incorporation of the liposome into the target cell. Choice of fusogenic 
lipid component is shown to be important, as DOPC has been observed to create these interaction 
structures much less effectively than DOPE [87].  Thus formulations consisting of an effective cationic 
lipid and effective fusogenic limit exhibit two of the major desired factors of a vector: interaction 
potential with the loaded genetic material and an effective method of introducing the load to a target. 
With these main lipid components considered, additional components of other origins can be included 
to further optimise or specialise the liposomal vector. PEG or PEGylated lipids can be incorporated, 
although it can be seen to act as a double-edged sword. While by intending to shield the surface of 
ƚŚĞ ůŝƉŽƐŽŵĞƐ ĨƌŽŵ ŚŽƐƚ ŝŵŵƵŶĞ ŝŶƚĞƌĂĐƚŝŽŶ ŝƚ ĐĂŶ ŝŶĐƌĞĂƐĞ ƚŚĞ ůŝƉŽƉůĞǆĞƐ ? ĂďŝůŝƚǇ ƚŽ ƚƌĂǀel in 
circulation [88], it conversely can decrease transfection and endosomal escape efficacy by the same 
surface-shielding mechanism [89].   
 
4. New methods for testing liposomal vaccine adjuvants 
To date, animal usage is in the forefront to evaluate immune response or immunogenicity of vaccine 
antigens with different adjuvants. However, a number of problems are encountered in the use of 
animal models such as the lack of reliable animal models, biological differences between animal 
models, differences in animal species and difference in responses of animal strains within the same 
species to various adjuvants. Most importantly, a major challenge to the generation of liposome 
adjuvants is the high use of animals required to test novel formulations from an early stage. Similarly, 
use of animals will have a major effect on cost effectiveness limiting the current in vivo screens for 
rapid liposome adjuvants development in future. To scale up liposome screening and maximize the 
benefit to human health using current approaches, large numbers of animals are necessary and the 
cost (in animals, cash and man-hours) is prohibitive. So, to look for in vitro testing methods may be a 
best alternative to screen large libraries of putative liposome adjuvant systems. Use of in vitro 
methods as a replacement for animal usage will also help in reducing the animal usage in early stage 
compound screening. However, ultimately animal testing of lead liposome adjuvants will be essential 
due to the regulatory requirements of vaccine development. 
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Dissecting the interaction of liposome adjuvants in vitro with important components of the innate 
immune system to define cellular and molecular mechanisms of action is a simple but promising 
approach that helps to assess behaviour of the liposome adjuvant formulation rapidly. As outlined 
above, induction of an immune response involves uptake and presentation of antigens in secondary 
lymphoid tissue, a key step that involves professional antigen presenting cells (APC: dendritic cells: 
DC; and macrophages: MØ). 
 
ŶƚŝŐĞŶƉĞƌƐŝƐƚĞŶĐĞ ?Ă ?ĚĞƉŽƚ ?ĞĨĨĞĐƚ ?ŝƐŝŵƉŽƌƚĂŶƚŝŶŝŵŵƵŶĞƐƚŝŵƵůĂƚŝŽŶĂŶĚƚƌĂŶƐƉŽƌƚŽĨĂŶƚŝŐĞŶƚŽ
lymph nodes occurs via cellular transport where upon introduction of an antigenic compound, through 
infection or immunization, immature resident and recruited APC will take up antigen and transport it 
to local draining lymph nodes. Thus an initial step in the process may involve attraction of APC to the 
antigen. This will then be followed by interaction and then activation of APC.  Methods for assessing 
each of these are outlined below. 
 
ATTRACTION is the ability of liposome adjuvant preparations to attract APC and may be screened in a 
variety of ways e.g. through the use of real-time cell migration system for the assay of directional cell 
migration or through the use of higher-throughput transwell-based systems using automated 
screening (e.g. the Cell-IQ system). Importantly the attraction of APC to sites of liposome injection will 
likely be crucial to the development of the depot effect that is highlighted as important to successful 
in vivo efficacy of preparations. Many studies have shown migration of APC (e.g. macrophages) 
towards established chemoattratants (e.g. MCP-1, apoptotic cells and apoptotic cell-derived 
microparticles) [62-64, 90, 91]. Here, migration speed and direction of the APC cultured on glass cover 
slips can be assessed by exposing them to liposomes (or other putative attractant) in a Dunn chamber 
chemotaxis system with live video microscopy.  Typical data generated from these microscopy studies 
is shown in figure 3. Our unpublished data has also shown differential migrational ability of 
macrophages and dendritic cells to different liposome adjuvant formulations using our Cell-IQ 
(Chipman Technologies) system or fully motorized, environment-controlled inverted DIC-microscopy 
system (Zeiss).  Thus applying this unique assay to in vitro bio-analyses of liposomes will be ideal to 
assess APC attraction towards the antigen.  
 
INTERACTION the ability of liposomes to associate with APC over time.  Attraction of APC towards 
liposome adjuvants will be followed by INTERACTION with the antigen/adjuvant and this can be 
assessed by flow cytometry based approaches. Association of fluorescent (e.g. DilC-labelled) 
liposomes when co-incubated with APC can be assessed by flow cytometric analysis [92]. Using this 
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approach, we have shown (figure 4) that liposome modulation by the addition of cholesterol 
(DDA:chol:TDB at 8:2:1 or 8:4:1 molar ratio) dramatically reduces interaction with MØ over time [92]. 
Importantly, this assay result correlates with a reduced ability for re-stimulated splenocytes of 
immunized animals to produce IFN-ɶĂŶĚ/>-2, important correlates of protective immunity (figure 5). 
Several studies have shown that IFN-ɶƉƌŽĚƵĐƚŝŽŶŝƐŝŵƉŽƌƚĂŶƚĨŽƌdǀĂĐĐŝŶĞĞĨĨŝĐĂĐǇ [42, 93] [94]. 
Furthermore, binding of internalized liposomes can be dissected through quenching surface bound 
fluorescence with trypan blue (to reveal only the fluorescent signal from internalized liposomes). 
Similarly, interaction assay can be undertaken at low temperature (non-permissive for particle uptake) 
to reveal only binding of liposomes to APC. This can also be carried out with antigen-loaded (adsorbed 
to the liposome surface or loaded in the core) liposomes and measures of fluorescent antigen can also 
be undertaken with multi-colour flow cytometry.  These approaches are similarly adaptable to 
conventional fluorescence microscopy. 
 
ACTIVATION/MATURATION. APC continuously sample their environment through uptake of material 
yet they do not constitutively induce responses, as they are quiescent. ACTIVATION from this 
quiescent state (by adjuvants with immunization without the need for PRR activation [95]; or damage, 
danger, PAMPs in natural infections) is a further crucial step in the generation of immune responses. 
A number of in vivo studies have shown that, following injection, DDA-based liposomes form a vaccine 
depot that mediates continuous attraction of APC to the site of injection [18] [26] [13] and that this 
depot effect correlates with immune response. These APC associate with liposomes and engulf, 
process and present the vaccine antigen and concomitantly become activated (assessed by up-
regulation of co-stimulatory molecules CD40 and CD86 [13]). 
 
The ability of liposomes to induce maturation and activation of APC is the critical event and can be 
assessed: (a) through immunofluorescence staining for key cell surface molecules/differentiation 
markers (CD14; MHC class II, CD1a, CD40, CD80, CD83, CD86, CD209) by multi-colour flow cytometry; 
(b) through the use of a multiplex cytokine assay screen by using either a flow cytometry-based or 
luminex based commercially available multiplex assay kits.  
 
Any single screen will be limited in its usefulness in predicting in vivo efficacy of any given adjuvant 
preparation.  An in vitro multiplex screen of key events that are essential for effective adjuvant 
function in vivo is required and a detailed in vitro multiplex analysis of liposome formulations with 
known in vivo efficacy is required to identify the necessary key tests.  Given the significant in vivo 
16 
 
testing of liposomes that has been undertaken in labs, including our own, around the world, this in 
vitro correlation is an important piece of work to be undertaken. 
 
5. Manufacturing hurdles faced in the progression of liposomal adjuvants to the market. 
In addition to effective testing of these systems, in the translation of liposomal adjuvants from 
laboratory studies to market a key rate-limiting factor has been the cost effective production of a 
stabilised product. As with liposomes for drug delivery, the physicochemical properties of the 
liposomes are critical to ensure efficacy and product quality and these physicochemical properties are 
influenced by the manufacturing method adopted. Therefore, it is vital that the critical quality 
attributes and the critical process parameters in their manufacture are identified for the target 
liposome product profile. Indeed, a particular issue related to the production of liposomal products is 
their sensitivity to changes in the manufacturing conditions, including changes in scale; if there are 
changes in critical manufacturing parameters, complete characterisation of the liposomal product is 
recommended and this can include in vivo studies. Therefore, to tackle this issue new methods for the 
production of liposomal adjuvants are required.  
 
The first method for preparing liposomes in the laboratory  remains popular to-date and is based on 
a simple lipid film hydration method described in the 1960s [96, 97]; this method can easily be adapted 
for a variety of lipid molecules in order to form liposomes. Here, lipid molecules are dissolved in an 
appropriate solvent, usually a mix of chloroform and methanol, which is evaporated under vacuum, 
leaving a dried lipid film on the bottom of a flask [96, 97]. Residues of solvent are eliminated by 
flushing the dried lipid film under a stream of nitrogen. Subsequent hydration with an aqueous buffer 
together with agitation allows for assembly of the lipid molecules into large multilamellar vesicles 
(MLV). The hydration is performed above the transition temperature of the lipids, in order to maintain 
the formation of the vesicles [96, 98]. Resulting MLV are usually highly polydisperse, varying in size 
and shape. However, the obvious limitation of this method for industrial high-throughput 
manufacturing is scalability and controlling the resulting vesicle size which is dictated by the choice of 
lipids, the aqueous hydration step and the temperatures [96, 99]. To reduce and control vesicle size, 
several downsizing methods are available; the most frequently applied ones include sonication, 
extrusion, high shear or high pressure homogenization, and microfluidizer methods.    
 
For large scale production, methods based on high shear fluid processors (e.g. Microfluidizer®) have 
been developed. Preformed MLV of high polydispersities are lead through an intensifier pump into 
the interaction chamber. Here, a high shear and high impact zone is created with shear rates up to 107 
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s-1 and channel dimensions between typically 50-300 microns [100]. The applied shear force deforms 
the fluid followed by the impact, where collision of the particles is induced (Figure 6A). The 
turbulences and high shear forces triggers the size reduction of the MLV into SUV [101], where the 
size of resulting liposomes is dictated by the number of cycles and pressures. This temperature-
controlled method allows for reduction of the liposome size down to 50 nm in diameter. Scalability 
has been demonstrated, and the methods are frequently applied for size reduction of emulsions, 
suspensions and liposome formulations. Nevertheless, the high shear forces may not be applicable for 
shear sensitive DNA or protein antigens [98, 102].  
 
5.1 Manufacture of liposomal adjuvants using microfluidics 
Liposomes generated by fluidics-methods are based on the replacement of the solvent by addition of 
the aqueous phase and can be seen as an extension of the ethanol injection method [103]. In this 
method, the formation of SUV is based on a precipitation of the lipids, once in contact with the 
aqueous media. The liposome size is controlled by defined injection rates [104] and resulting liposome 
sizes can be tightly regulated. Methods based on the controlled fluid handling have been developed 
to increase the process robustness and manufacturing limitations of top-down methods. Solvents 
used are often less harsh than in the mechanical top-down methods, allowing for a simpler transfer 
into large-scale production. The rapid injection of the aqueous media into the solvent stream leads to 
a subsequent precipitation of the lipids, forming liposomes. Those methods based on rapid injection 
are common practice for large scale manufacturing of liposomes; mainly due to their scalability, 
flexibility and ease of application [102, 105] ?/ŶĐŽŶƚƌĂƐƚƚŽƚŚĞŵĞĐŚĂŶŝĐĂů “top-ĚŽǁŶ ?ŵĞƚŚŽĚƐ ?ƚŚĞ
ĨůƵŝĚŝŶũĞĐƚŝŽŶŵĞƚŚŽĚƐĐĂŶďĞĐĂƚĞŐŽƌŝǌĞĚĂƐ “ďŽƚƚŽŵ-ƵƉ ?ŵĞƚŚŽĚƐ ?ĂƐƚŚĞƉƌĞĐŝƉŝƚĂƚŝŽŶůĞĂĚƐƚŽƚŚĞ
formation of SUV without the need of further introducing mechanical forces for subsequent size 
reduction.  
 
Microfluidics-based methods are adapted methods of fluid-controlled bottom-up methods, reported 
for precise control of liposome sizes and have been developed to circumvent the lack of process 
robustness and control in mentioned top-down methods and aid the process development on a small-
footprint high-throughput device. Microfluidics generally considers fluid volumes handled in a 
constrained volume, allowing for precise control of mixing and flow rates and achieving a tight control 
of mixing rates, dominated by diffusion in a laminar flow profile. The rising demand of high-throughput 
tools in pharmaceutical and biopharmaceutical development led to an increase in number of 
microfluidics-based methodologies [106, 107]. Besides the enhanced process control, microfluidics-
based methods allow for a robust and reproducible liposome manufacturing, based on the controlled 
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polarity increase in the chamber. It has been suggested that the formation of liposomes is driven by a 
nanoprecipitation reaction, where after supersaturation aggregation of the lipid molecules dominates 
once diluted beyond their aqueous solubility, striving the formation of the smallest particle size 
possible. Here, the liposomes formation is dependent on the ratio and flow rates of solvent and 
aqueous streams, which takes place at laminar flow conditions and mixing is driven by diffusion and 
chaotic advection. The tight control of the resulting liposome sizes is triggered by laminar flow profiles 
in the microfluidic chambers.  
 
Microfluidic-based methods can be used to replicate a large scale process on a chip in microscale. One 
example is the liposome extrusion process, which is used on a large scale for size reduction of 
multilamellar liposomes by several passages through a membrane [108]. A liposome extrusion process 
on a chip has been developed, where lipid vesicles and tubes were manufactured, combining top-
down and bottom-up vesicle manufacturing in an on-chip design. The pressure difference was one 
factor shown to contribute to the overall form of the final lipid vesicles  [109]. A further adaption into 
microscale from large-scale liposome manufacturing is the development of an on-chip double 
emulsion method. This involves, initial formation of a lipid emulsion followed by removal of the oil 
phase. Lipid monolayers formed at the interfaces assemble to lipid bilayer vesicles. This process has 
been translated into a microfluidic device, with a less harsh solvent than in the conventional double 
emulsion method allowing for higher biocompatibility [110]. This method was successfully shown to 
encapsulate protein, microbeads and cells [111]. The variable encapsulation efficiency was shown to 
depend on applied flow rates during the emulsification process, a user-controlled factor emphasizing 
the adaptability of microfluidic processes. 
 
The flow-focusing technique [112-114] allows for a centred stream of solvent within two streams of 
polar phase. The diffusively driven process is the basis for controlled sizes for resulting particles (Figure 
6B). The volumetric flow rates dictate the sizes of the resulting hydrodynamically focused solvent 
stream, where solvent dilutions result in self-assembly of the liposomes. The width of the 
hydrodynamically focused lipid-stream is proportional to the flow rates applied in the system. 
Liposomes manufactured with the hydrodynamic focusing method range between 50-150 nm in size. 
The channel depth and aspect ratio has been shown to strongly influence the resulting velocity profile 
homogeneity as well as surface effects [112, 113, 115]. The process of liposome formation is 
continuous, with the size dependent on flow ratios of aqueous and solvent phase and flow rates. 
Nevertheless, applied flow rate ratios between 10 to 60 will lead to a dilution of the final liposome 
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formulation and might necessitate a concentration step post formation. Flow rates reported are as 
low as 200 mm/sec [116, 117]. 
 
A passive micromixer based on chaotic advection [118] has also been applied for size-controlled 
synthesis of liposomes and lipid nanoparticles (Figure 6c).  Higher flow rate ratios are reported to 
result in smaller liposome particles, driven by the overall lower amount of residual solvent present, 
reducing particle fusion (Ostwald ripening). Optimal flow rate ratios reported range around 3, with 
reduces the dilution effect opposed to higher ratios employed in the flow-focusing method [119]. 
Diffusional mixing is enhances by the herringbone structures on the channel wall, resulting in much 
quicker mixing profiles compared to the flow-focusing technique. Here, the flow ratio of aqueous to 
solvent stream has been associated as the most influential factor contributing to the final size 
distribution of resulting liposome formulation [120], allowing for combined liposome manufacturing 
and drug encapsulation in a single process step [121]. 
 
In both methods, chaotic advection micromixer and flow focusing, the scalability of respective method 
has been shown and associated with constant vesicle sizes throughout a range of flow rates at 
constant flow ratios [115, 122]. The SHM method was shown to reproducibly manufacture SUV of 
controlled sizes at flow rates higher than 70 mL/min by parallelization of the mixers (scale-out). 
Overall, flow rates applied with the chaotic advection method are higher yielding a higher throughout. 
Furthermore, dilution is much higher in the flow focusing method with flow ratios ranging up to 60, 
whereas in a chaotic advection process a ratio of 3 was shown to yield the smallest vesicle size 
possible. Generally, bottom-up methods allow for a higher degree of process control and uniformity 
of resulting vesicles, circumventing the manufacturing process as the rate limiting factor in liposome 
manufacturing. 
 
5.2 Implementing quality in liposomal adjuvant manufacturing by Quality by Design. 
Along with recent trends in the pharmaceutical sector, Quality by Design (QbD) principles have been 
investigated for liposomal products, generating a robust and reproducible design space that allows for 
controlled liposome quality characteristics. QbD principles aid the formulation process and evaluate 
the critical variables in a process, with the overall aim of applying statistical process control for 
achieving an enhanced product quality. A recent study investigated the effect of lipid chain length, 
lipid and drug concentration on the drug encapsulation efficiency. These parameters were 
furthermore linked to the liposome particle size, zeta-potential, as well as drug encapsulation 
efficiency in a response surface model. Here, the link between manufacturing method and particle 
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size was determined statistically, and furthermore linked the amount of drug encapsulated to a uni-
lamellar vesicle structure [123]. Furthermore, a QbD study on liposomes investigated initially eight 
variables (lipid concentration, drug concentration, cholesterol concentration, buffer concentration, 
hydration time, sonication time, freeze Wthaw cycles and extrusion pressure) on their effect to the 
critical liposome characteristics size, stability and drug encapsulation. The study revealed that the lipid 
and drug concentration had the main effect on the drug encapsulation efficiency [124]. Those studies 
give an example of how QbD principles may be used for aiding process understanding and optimizing 
a formulation. Nevertheless, results are dependent on the choice of lipids and drug and a design space 
requires optimization for each separate formulation. 
 
However the above studies only considered the links for composition and manufacture to physico-
chemical attributes. This is useful when the characteristics of a liposomal vaccine are identified. 
However, as we have discussed the correlation between physico-chemical attributes and vaccine 
efficacy is multi-factorial. Therefore in recent study, we used multivariate analysis (MVA) to consider 
correlations between key liposomal adjuvant characteristics to in-vivo immune responses [125]. Here, 
the main liposomal characteristics (liposome size, zeta potential) were determined by addition of a 
post-exposure fusion tuberculosis vaccine. In-vivo derived immunological performances (IgG, IgG1, 
IgG2b, spleen proliferation, IL-2, IL-5, IL-6, IL-10, IFN-ɶ) were clustered and linked to the characteristics 
of the adjuvant in a partial least square regression analysis and linked to the lipid composition. The 
model identified the drift towards a cell mediated immunity dependent on cationic lipid content and 
the resulting physicochemical liposome properties, exemplifying the use of chemometrics-based 
methods for aiding adjuvant design. 
 
6. Conclusions 
New vaccines are required to offer improved worldwide healthcare. These vaccines should be safe, 
effective, affordable and accessible to the global population.  Vaccine adjuvants play a key role in 
improving vaccine efficacy and stability. Liposomes, due to their proven clinical record as delivery 
systems and versatility, offer a strong adjuvant platform. Recent advances in manufacturing also make 
these a cost-effective option. However to continue to develop these systems as adjuvants we need to 
build a better understanding of the parameters that promote their efficacy, and this require us 
revisiting previously accepted paradigms in liposomal designs to take into account new advances in 
vaccinology. Using our new understanding of immune cell biology, we can modify liposomes not only 
effectively carrier antigens but also improve cellular interactions by targeting PRR to promote strong 
and appropriate immune cell activation. Furthermore, new development in manufacturing processes 
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now allow us to translate liposome production from the laboratory setting to industrial scale rapidly. 
However to improve the identification of effective adjuvants and speed their journey to market, new 
rapid in vitro pre-screen tools are need.  Only through tackling all these issues can liposomal-adjuvants 
support the need for new vaccines.   
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Figure legends. 
 
Figure 1. Liposomal adjuvants may function through the formation of an antigen (Ag)-adjuvant depot 
that promotes antigen delivery, uptake by immature antigen presenting cells (APC) 
and cellular stimulation through pattern recognition receptors (PRR). This results in maturation of APC 
(up-regulation of MHC II and co-stimulatory molecules) and antigen processing and presentation.      
 
Figure 2. Key phyisco-chemical features of liposomes that can influence their efficacy as vaccine 
adjuvants including bilayer rigidity [12,13,14,15,16,17,18], vesicle size vesicles [19-23], biodistribution 
[24], biodistribution, antigen location [25] and vesicle charge [31] 
 
Figure 3. Analysis of APC migration.  Macrophages seeded to glass coverslips and loaded to a Dunn 
chemotaxis chamber are followed for their migration towards a putative attractant.  The migration of 
cells is assessed using time-lapse photomicrography over two hours and the path taken by each cell is 
superimposed on the plot shown.  The starting point of each cell is mapped onto the cross hairs, the 
final position of the cell is shown by the black circle and the route shown in between.  Blue dot: relative 
position of the attractant. 
 
Figure 4: Liposomes modified by the addition of cholesterol show reduced interaction with 
macrophages.  THP-1 cell derived macrophages were incubated with fluorescent (dilC)-labelled 
liposomes and the interaction of fluorescent liposomes with macrophages was assessed by flow 
cytometry. Data shown are the mean or Mean Fluorescence Intensity (MFI) versus % of cells positive 
for fluorescence from three independent experiments.  Three DDA:Cholesterol:TDB liposome 
formulations were used at molar ratios of 8:0:1 (blue); 8:2:1 (green) and 8:4:1 (red).  Results for 
macrophages alone are shown in black.  Addition of cholesterol significantly reduces liposome 
interaction. 
 
Figure 5: Liposomes modified by the addition of cholesterol generate reduced antigen-specific 
cytokine responses.  Mice (n=5) were immunised with Ag in formulation with the indicated 
DDA:cholesterol:TDB liposomes.  Ex vivo splenocyte cytokine production was assessed. Data shown 
are mean ± SEM.  Response from Ag-only immunisation: IFN = 100±90 pg/ml; IL2 = 88±88pg/ml. 
 
Figure 6: Novel methods for large scale production of liposomes. A) high shear fluid processors  where 
preformed MLV are subjected to a high shear and high impact zone. The applied shear force deforms 
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the fluid followed by the impact, where collision of the particles is induced to reduce vesicle size. 
Vesicle size is controlled by the number of cycles and pressures. Microfluidics systems using B) flow 
focusing or C) chaotic advection micromixer where vesicle size can be controlled through flow rates 
and flow ratios. 
 
 
